TP53: An oncogene in disguise

Cell Death and Differentiation

Volumn 22, Issue 8, 2015, Pages 1239-1249

  Soussi, T ^a,b,c,d   Wiman, K G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SORBONNE UNIVERSITÉ   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; IMATINIB; ONCOPROTEIN; PROTEIN VARIANT; TRASTUZUMAB; 1-(PROPOXYMETHYL)MALEIMIDE; 2,2-BIS(HYDROXYMETHYL)-1-AZABICYCLO(2,2,2,)OCTAN-3-ONE; FUSED HETEROCYCLIC RINGS; HETEROCYCLIC COMPOUND; MALEIMIDE DERIVATIVE; PROTEIN P53;

CANCER THERAPY; GAIN OF FUNCTION MUTATION; GENETIC VARIABILITY; GENOME; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR GENE; TUMOR PROTEIN P53 GENE; TUMOR SUPPRESSOR GENE; ANIMAL; GENETICS; METABOLISM; MUTATION;

AMORPHA;

ANIMALS; AZA COMPOUNDS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; HUMANS; MALEIMIDES; MUTATION; PHENOTYPE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84935685694     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.53     Document Type: Review

References (100)

1. Garraway LA, Lander ES. Lessons from the cancer genome. Cell 2013; 153: 17-37.
2. Koboldt DC, Steinberg KM, Larson DE, Wilson RK, Mardis ER. The next-generation sequencing revolution and its impact on genomics. Cell 2013; 155: 27-38.
3. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502: 333-339.
4. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LAJ, Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546-1558.
5. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-218.
6. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science 2011; 331: 1553-1558.
7. Workman P, Al-Lazikani B. Drugging cancer genomes. Nat Rev Drug Discov 2013; 12: 889-890.
8. Harris H, Miller OJ, Klein G, Worst P, Tachibana T. Suppression of malignancy by cell fusion. Nature 1969; 223: 363-368.
9. Knudson A. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-823.
10. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983; 305: 779-784.
11. Haber D, Harlow E. Tumour-suppressor genes: evolving definitions in the genomic age. Nat Genet 1997; 16: 320-322.
12. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997; 386: 763.
13. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271.
14. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003; 33: 416-421.
15. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244: 217-221.
16. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246: 491-494.
17. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007; 12: 303-312.
18. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev 2012; 26: 1268-1286.
19. Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat 2014; 35: 672-688.
20. Soussi T. Advances in carcinogenesis: a historical perspective from observational studies to tumor genome sequencing and TP53 mutation spectrum analysis. Biochim Biophys Acta 2011; 1816: 199-208.
21. Joerger AC, Fersht AR. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol 2010; 2: a000919.
22. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013; 45: 1113-1120.
23. Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16: 121-130.
24. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2: 811-814.
25. Zenz T, Vollmer D, Trbusek M, Smardova J, Benner A, Soussi T et al. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 2010; 24: 2072-2079.
26. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6: 1699-1703.
27. Benchimol S, Pim D, Crawford L. Radioimmunoassay of the cellular protein p53 in mouse and human cell lines. EMBO J 1982; 1: 1055-1062.
28. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008; 22: 1337-1344.
29. Hock AK, Vousden KH. The role of ubiquitin modification in the regulation of p53. Biochim Biophys Acta 2014; 1843: 137-149.
30. Pant V, Lozano G. Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev 2014; 28: 1739-1751.
31. Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F et al. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res 2011; 9: 577-588.
32. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990; 9: 1595-1602.
33. Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER, Vogelstein B et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the 'hot spot' mutant phenotypes. Cell Growth Differ 1990; 1: 571-580.
34. Ory K, Legros Y, Auguin C, Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 1994; 13: 3496-3504.
35. Milner J. A conformation hypothesis for the suppressor and promoter functions of p53 in cell growth control and in cancer. Proc Biol Sci 1991; 245: 139-145.
36. Wong KB, DeDecker BS, Freund SM, Proctor MR, Bycroft M, Fersht AR. Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc Natl Acad Sci USA 1999; 96: 8438-8442.
37. Bullock AN, Henckel J, DeDecker BS, Johnson CM, Nikolova PV, Proctor MR et al. Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci USA 1997; 94: 14338-14342.
38. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265: 346-355.
39. Halevy O, Michalovitz D, Oren M. Different tumor-derived p53 mutants exhibit distinct biological activities. Science 1990; 250: 113-116.
40. Kawaguchi T, Kato S, Otsuka K, Watanabe G, Kumabe T, Tominaga T et al. The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library. Oncogene 2005; 24: 6976-6981.
41. Kakudo Y, Shibata H, Otsuka K, Kato S, Ishioka C. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res 2005; 65: 2108-2114.
42. Shiraishi K, Kato S, Han SY, Liu W, Otsuka K, Sakayori et al. Isolation of temperaturesensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem 2004; 279: 348-355.
43. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003; 100: 8424-8429.
44. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010; 2: a001107.
45. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013; 15: 2-8.
46. Donzelli S, Biagioni F, Fausti F, Strano S, Fontemaggi G, Blandino G. Oncogenomic approaches in exploring gain of function of mutant p53. Curr Genomics 2008; 9: 200-207.
47. Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 2014; 14: 359-370.
48. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore et al. Gain of function mutations in p53. Nat Genet 1993; 4: 42-46.
49. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet 2013; 45: 1127-1133.
50. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 2010; 17: 273-285.
51. Dell'orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, Levrero et al. ChIP-on-Chip analysis of in vivo mutant p53 binding to selected gene promoters. OMICS 2011; 15: 305-312.
52. Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H et al. Mutant p53 gain-offunction induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 2013; 32: 3286-3295.
53. Santoro R, Strano S, Blandino G. Transcriptional regulation by mutant p53 and oncogenesis. Subcell Biochem 2014; 85: 91-103.
54. Zhou G, Wang J, Zhao M, Xie TX, Tanaka N, Sano D et al. Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. Mol Cell 2014; 54: 960-974.
55. Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X et al. Tumour-associated mutant p53 drives the Warburg effect. Nat Commun 2013; 4: 2935.
56. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominantnegative activities. Mol Cell 1998; 2: 305-316.
57. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809-819.
58. Di Como CJ, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999; 19: 1438-1449.
59. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003; 3: 387-402.
60. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 2001; 21: 1874-1887.
61. Li Y, Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 2007; 26: 2220-2225.
62. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012; 149: 1269-1283.
63. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011; 145: 571-583.
64. Valente LJ, Gray DH, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL et al. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep 2013; 3: 1339-1345.
65. Hock AK, Vousden KH. Tumor suppression by p53: fall of the triumvirate? Cell 2012; 149: 1183-1185.
66. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CAJ, Butel JS et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-221.
67. Donehower LA, Lozano G. 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 2009; 9: 831-841.
68. Kenzelmann Broz D, Attardi LD. In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models. Carcinogenesis 2010; 31: 1311-1318.
69. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861-872.
70. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-860.
71. Ludwig RL, Bates S, Vousden KH. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 1996; 16: 4952-4960.
72. Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, El-Naggar AK et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 2004; 36: 63-68.
73. Khoo KH, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov 2014; 13: 217-236.
74. Bykov VJ, Wiman KG. Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett 2014; 588: 2622-2627.
75. Wilcken R, Wang G, Boeckler FM, Fersht AR. Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition. Proc Natl Acad Sci USA 2012; 109: 13584-13589.
76. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 2008; 105: 10360-10365.
77. Liu X, Wilcken R, Joerger AC, Chuckowree IS, Amin J, Spencer J et al. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res 2013; 41: 6034-6044.
78. Yu X, Vazquez A, Levine AJ, Carpizo DR. Allele-specific p53 mutant reactivation. Cancer Cell 2012; 21: 614-625.
79. Yu X, Blanden AR, Narayanan S, Jayakumar L, Lubin D, Augeri D et al. Small molecule restoration of wildtype structure and function of mutant p53 using a novel zincmetallochaperone based mechanism. Oncotarget 2014; 5: 8879-8892.
80. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8: 282-288.
81. Bykov VJ, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J et al. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 2005; 280: 30384-30391.
82. Bykov VJ, Zache N, Stridh H, Westman J, Bergman J, Selivanova G et al. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 2005; 24: 3484-3491.
83. Lambert JM, Moshfegh A, Hainaut P, Wiman KG, Bykov VJ. Mutant p53 reactivation by PRIMA-1(MET) induces multiple signaling pathways converging on apoptosis. Oncogene 2009; 29: 1329-1338.
84. Wassman CD, Baronio R, Demir O, Wallentine BD, Chen CK, Hall LV et al. Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nat Commun 2013; 4: 1407.
85. Lehmann S, Bykov VJ, Ali D, Andren O, Cherif H, Tidefelt U et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 2012; 30: 3633-3639.
86. Peng X, Zhang MQ, Conserva F, Hosny G, Selivanova G, Bykov VJ et al. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis 2013; 4: e881.
87. Tessoulin B, Descamps G, Moreau P, Maiga S, Lode L, Godon C et al. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. Blood 2014; 124: 1626-1636.
88. Kravchenko JE, Ilyinskaya GV, Komarov PG, Agapova LS, Kochetkov DV, Strom E et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci USA 2008; 105: 6302-6307.
89. Floquet C, Deforges J, Rousset JP, Bidou L. Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res 2011; 39: 3350-3362.
90. Muller HJ. Further studies on the nature and causes of gene mutations. Int Congr Genet 1932; 6: 231-255.
91. Cox C, Bignell G, Greenman C, Stabenau A, Warren W, Stephens P et al. A survey of homozygous deletions in human cancer genomes. Proc Natl Acad Sci USA 2005; 102: 4542-4547.
92. Rowan AJ, Lamlum H, Ilyas M, Wheeler J, Straub J, Papadopoulou A et al. APC mutations in sporadic colorectal tumors: A mutational 'hotspot' and interdependence of the 'two hits'. Proc Natl Acad Sci USA 2000; 97: 3352-3357.
93. Herskowitz I. Functional inactivation of genes by dominant negative mutations. Nature 1987; 329: 219-222.
94. Natan E, Hirschberg D, Morgner N, Robinson CV, Fersht AR. Ultraslow oligomerization equilibria of p53 and its implications. Proc Natl Acad Sci USA 2009; 106: 14327-14332.
95. Wang Y, Suh YA, Fuller MY, Jackson JG, Xiong S, Terzian T et al. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest 2011; 121: 893-904.
96. Scuoppo C, Miething C, Lindqvist L, Reyes J, Ruse C, Appelmann I et al. A tumour suppressor network relying on the polyamine-hypusine axis. Nature 2012; 487: 244-248.
97. Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 2007; 104: 5569-5574.
98. Cirstea IC, Gremer L, Dvorsky R, Zhang SC, Piekorz RP, Zenker et al. Diverging gain-offunction mechanisms of two novel KRAS mutations associated with Noonan and cardiofacio-cutaneous syndromes. Hum Mol Genet 2013; 22: 262-270.
99. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010; 465: 966.
100. Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 2014; 25: 304-317.